Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 641 entries
Sorted by: Best Match Show Resources per page
Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout.

Journal of pharmacy practice

Huneycutt E, Board C, Clements JN.
PMID: 28980503
J Pharm Pract. 2017 Jan 01;897190017734427. doi: 10.1177/0897190017734427. Epub 2017 Jan 01.

OBJECTIVE: To review the pharmacokinetics, clinical efficacy, safety, and role of lesinurad for the management of hyperuricemia associated with gout.DATA SELECTION: A MEDLINE search (2000 to April 2017) was conducted using the terms hyperuricemia, gout, URAT-1, URAT-1 transporter, and...

Cite
Huneycutt E, Board C, Clements JN. Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout. J Pharm Pract. 2017;897190017734427doi: 10.1177/0897190017734427.
Huneycutt, E., Board, C., & Clements, J. N. (2017). Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout. Journal of pharmacy practice, 897190017734427. https://doi.org/10.1177/0897190017734427
Huneycutt, Emily, et al. "Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout." Journal of pharmacy practice vol. (2017): 897190017734427. doi: https://doi.org/10.1177/0897190017734427
Huneycutt E, Board C, Clements JN. Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout. J Pharm Pract. 2017 Jan 01;897190017734427. doi: 10.1177/0897190017734427. Epub 2017 Jan 01. PMID: 28980503.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Chaabane A, Aouam K, Fredj NB, Boughattas NA.
PMID: 27393273
Therapie. 2010 Nov-Dec;65(6):543-50. doi: 10.2515/therapie/2010072.

AIM: Study the epidemiological, clinical, biological and chronological drug rash with eosinophilia and systemic symptoms (DRESS) characteristic and indicate the implicated drugs.METHODS: We carried a retrospective study including all DRESS cases notified to the Pharmacovigilance Unit of Monastir.RESULTS: Our...

Cite
Chaabane A, Aouam K, Fredj NB, et al. DRESS syndrome : étude de 11 cas et revue de la littérature. [Not Available]. Therapie. 2010;65(6):543-50doi: 10.2515/therapie/2010072.
Chaabane, A., Aouam, K., Fredj, N. B., & Boughattas, N. A. (2010). DRESS syndrome : étude de 11 cas et revue de la littérature. [Not Available]. Therapie, 65(6), 543-50. https://doi.org/10.2515/therapie/2010072
Chaabane, Amel, et al. "DRESS syndrome : étude de 11 cas et revue de la littérature." [Not Available]. Therapie vol. 65,6 (2010): 543-50. doi: https://doi.org/10.2515/therapie/2010072
Chaabane A, Aouam K, Fredj NB, Boughattas NA. DRESS syndrome : étude de 11 cas et revue de la littérature. [Not Available]. Therapie. 2010 Nov-Dec;65(6):543-50. doi: 10.2515/therapie/2010072. French. PMID: 27393273.
Copy Download .nbib Format: NLM
Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

Dursun AB, Sahin OZ.
PMID: 25685161
Allergy Asthma Clin Immunol. 2014 Oct 22;10(1):52. doi: 10.1186/1710-1492-10-52. eCollection 2014.

BACKGROUND: Allopurinol is an effective urate-lowering drug that is well tolerated by the majority of patients. Patients with chronic renal insufficiency have an increased risk of hypersensitivity reactions with allopurinol.CASE PRESENTATION: 75 year old male patient with gout, renal...

Cite
Dursun AB, Sahin OZ. Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report. Allergy Asthma Clin Immunol. 2014;10(1):52doi: 10.1186/1710-1492-10-52.
Dursun, A. B., & Sahin, O. Z. (2014). Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 10(1), 52. https://doi.org/10.1186/1710-1492-10-52
Dursun, Adile Berna, and Sahin, Osman Z. "Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 10,1 (2014): 52. doi: https://doi.org/10.1186/1710-1492-10-52
Dursun AB, Sahin OZ. Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report. Allergy Asthma Clin Immunol. 2014 Oct 22;10(1):52. doi: 10.1186/1710-1492-10-52. eCollection 2014. PMID: 25685161; PMCID: PMC4326512.
Copy Download .nbib Format: NLM
Thermostable Xanthine Oxidase Activity from Bacillus pumilus RL-2d Isolated from Manikaran Thermal Spring: Production and Characterization.

Indian journal of microbiology

Sharma NK, Thakur S, Thakur N, Savitri, Bhalla TC.
PMID: 26843701
Indian J Microbiol. 2016 Mar;56(1):88-98. doi: 10.1007/s12088-015-0547-3. Epub 2015 Aug 21.

Xanthine oxidase is an important enzyme of purine metabolism that catalyzes the hydroxylation of hypoxanthine to xanthine and then xanthine to uric acid. A thermostable xanthine oxidase is being reported from a thermophilic organism RL-2d isolated from the Manikaran...

Cite
Sharma NK, Thakur S, Thakur N, et al. Thermostable Xanthine Oxidase Activity from Bacillus pumilus RL-2d Isolated from Manikaran Thermal Spring: Production and Characterization. Indian J Microbiol. 2015;56(1):88-98doi: 10.1007/s12088-015-0547-3.
Sharma, N. K., Thakur, S., Thakur, N., Savitri, & Bhalla, T. C. (2016). Thermostable Xanthine Oxidase Activity from Bacillus pumilus RL-2d Isolated from Manikaran Thermal Spring: Production and Characterization. Indian journal of microbiology, 56(1), 88-98. https://doi.org/10.1007/s12088-015-0547-3
Sharma, Nirmal Kant, et al. "Thermostable Xanthine Oxidase Activity from Bacillus pumilus RL-2d Isolated from Manikaran Thermal Spring: Production and Characterization." Indian journal of microbiology vol. 56,1 (2016): 88-98. doi: https://doi.org/10.1007/s12088-015-0547-3
Sharma NK, Thakur S, Thakur N, Savitri, Bhalla TC. Thermostable Xanthine Oxidase Activity from Bacillus pumilus RL-2d Isolated from Manikaran Thermal Spring: Production and Characterization. Indian J Microbiol. 2016 Mar;56(1):88-98. doi: 10.1007/s12088-015-0547-3. Epub 2015 Aug 21. PMID: 26843701; PMCID: PMC4729748.
Copy Download .nbib Format: NLM
Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome.

Turkish journal of haematology : official journal of Turkish Society of Haematology

İrken G, Ören H, Öniz H, Çetingül N, Vergin C, Atabay B, Gülen H, Türker M, Kantar M, Yılmaz Ş.
PMID: 27265481
Turk J Haematol. 2006 Sep 05;23(3):142-6.

Hyperleukocytosis, defined as a peripheral leukocyte count ≥ 100x109/L, is seen in 5-20% of newly diagnosed cases of childhood leukemia and is a poor prognostic factor. In this study, we aimed to examine the presenting clinical and laboratory features,...

Cite
İrken G, Ören H, Öniz H, et al. Çocukluk çağı akut lenfoblastik lösemisinde hiperlökositoz: komplikasyonlar, tedavi, prognoz. Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome. Turk J Haematol. 2006;23(3):142-6
İrken, G., Ören, H., Öniz, H., Çetingül, N., Vergin, C., Atabay, B., Gülen, H., Türker, M., Kantar, M., & Yılmaz, �. �. (2006). Çocukluk çağı akut lenfoblastik lösemisinde hiperlökositoz: komplikasyonlar, tedavi, prognoz. Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome. Turkish journal of haematology : official journal of Turkish Society of Haematology, 23(3), 142-6.
İrken, Gülersu, et al. "Çocukluk çağı akut lenfoblastik lösemisinde hiperlökositoz: komplikasyonlar, tedavi, prognoz." Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome. Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 23,3 (2006): 142-6.
İrken G, Ören H, Öniz H, Çetingül N, Vergin C, Atabay B, Gülen H, Türker M, Kantar M, Yılmaz Ş. Çocukluk çağı akut lenfoblastik lösemisinde hiperlökositoz: komplikasyonlar, tedavi, prognoz. Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome. Turk J Haematol. 2006 Sep 05;23(3):142-6. PMID: 27265481.
Copy Download .nbib Format: NLM
Linking uric acid metabolism to diabetic complications.

World journal of diabetes

Kushiyama A, Tanaka K, Hara S, Kawazu S.
PMID: 25512781
World J Diabetes. 2014 Dec 15;5(6):787-95. doi: 10.4239/wjd.v5.i6.787.

Hyperuricemia have been thought to be caused by the ingestion of large amounts of purines, and prevention or treatment of hyperuricemia has intended to prevent gout. Xanthine dehydrogenase/xanthine oxidase (XDH/XO) is rate-limiting enzyme of uric acid generation, and allopurinol...

Cite
Kushiyama A, Tanaka K, Hara S, et al. Linking uric acid metabolism to diabetic complications. World J Diabetes. 2014;5(6):787-95doi: 10.4239/wjd.v5.i6.787.
Kushiyama, A., Tanaka, K., Hara, S., & Kawazu, S. (2014). Linking uric acid metabolism to diabetic complications. World journal of diabetes, 5(6), 787-95. https://doi.org/10.4239/wjd.v5.i6.787
Kushiyama, Akifumi, et al. "Linking uric acid metabolism to diabetic complications." World journal of diabetes vol. 5,6 (2014): 787-95. doi: https://doi.org/10.4239/wjd.v5.i6.787
Kushiyama A, Tanaka K, Hara S, Kawazu S. Linking uric acid metabolism to diabetic complications. World J Diabetes. 2014 Dec 15;5(6):787-95. doi: 10.4239/wjd.v5.i6.787. PMID: 25512781; PMCID: PMC4265865.
Copy Download .nbib Format: NLM
Viruses may trigger allopurinol hypersensitivity syndrome.

NDT plus

Koike M, Kanno Y, Tomori K, Okada H, Suzuki H.
PMID: 25983906
NDT Plus. 2008 Aug;1(4):273-4. doi: 10.1093/ndtplus/sfn042.

No abstract available.

Cite
Koike M, Kanno Y, Tomori K, et al. Viruses may trigger allopurinol hypersensitivity syndrome. NDT Plus. 2008;1(4):273-4doi: 10.1093/ndtplus/sfn042.
Koike, M., Kanno, Y., Tomori, K., Okada, H., & Suzuki, H. (2008). Viruses may trigger allopurinol hypersensitivity syndrome. NDT plus, 1(4), 273-4. https://doi.org/10.1093/ndtplus/sfn042
Koike, Masami, et al. "Viruses may trigger allopurinol hypersensitivity syndrome." NDT plus vol. 1,4 (2008): 273-4. doi: https://doi.org/10.1093/ndtplus/sfn042
Koike M, Kanno Y, Tomori K, Okada H, Suzuki H. Viruses may trigger allopurinol hypersensitivity syndrome. NDT Plus. 2008 Aug;1(4):273-4. doi: 10.1093/ndtplus/sfn042. PMID: 25983906; PMCID: PMC4421215.
Copy Download .nbib Format: NLM
Clinical Application of Pharmacogenetics: Where are We Now?.

EJIFCC

van Schaik RH.
PMID: 27683445
EJIFCC. 2013 Feb 21;24(3):105-12. eCollection 2013 Feb.

Pharmacogenetic (PGx) testing has the potential to improve drug therapy in an individual by informing appropriate drug dosing or drug selection in order to maximize efficacy and safety. Although multiple studies have illustrated the potential benefits of such testing...

Cite
van Schaik RH. Clinical Application of Pharmacogenetics: Where are We Now?. EJIFCC. 2013;24(3):105-12
van Schaik, R. H. (2013). Clinical Application of Pharmacogenetics: Where are We Now?. EJIFCC, 24(3), 105-12.
van Schaik, Ron Hn. "Clinical Application of Pharmacogenetics: Where are We Now?." EJIFCC vol. 24,3 (2013): 105-12.
van Schaik RH. Clinical Application of Pharmacogenetics: Where are We Now?. EJIFCC. 2013 Feb 21;24(3):105-12. eCollection 2013 Feb. PMID: 27683445; PMCID: PMC4975184.
Copy Download .nbib Format: NLM
Evaluation of antigout activity of Phyllanthus emblica fruit extracts on potassium oxonate-induced gout rat model.

Veterinary world

Sarvaiya VN, Sadariya KA, Pancha PG, Thaker AM, Patel AC, Prajapati AS.
PMID: 27047023
Vet World. 2015 Oct;8(10):1230-6. doi: 10.14202/vetworld.2015.1230-1236. Epub 2015 Oct 23.

AIM: The present study has been conducted to evaluate antigout activity of aqueous and alcoholic extracts of Phyllanthus emblica fruits following its 28 days repeated oral administration on potassium oxonate-induced gout rat model.MATERIALS AND METHODS: The study was conducted...

Cite
Sarvaiya VN, Sadariya KA, Pancha PG, et al. Evaluation of antigout activity of Phyllanthus emblica fruit extracts on potassium oxonate-induced gout rat model. Vet World. 2015;8(10):1230-6doi: 10.14202/vetworld.2015.1230-1236.
Sarvaiya, V. N., Sadariya, K. A., Pancha, P. G., Thaker, A. M., Patel, A. C., & Prajapati, A. S. (2015). Evaluation of antigout activity of Phyllanthus emblica fruit extracts on potassium oxonate-induced gout rat model. Veterinary world, 8(10), 1230-6. https://doi.org/10.14202/vetworld.2015.1230-1236
Sarvaiya, Vaidehi N, et al. "Evaluation of antigout activity of Phyllanthus emblica fruit extracts on potassium oxonate-induced gout rat model." Veterinary world vol. 8,10 (2015): 1230-6. doi: https://doi.org/10.14202/vetworld.2015.1230-1236
Sarvaiya VN, Sadariya KA, Pancha PG, Thaker AM, Patel AC, Prajapati AS. Evaluation of antigout activity of Phyllanthus emblica fruit extracts on potassium oxonate-induced gout rat model. Vet World. 2015 Oct;8(10):1230-6. doi: 10.14202/vetworld.2015.1230-1236. Epub 2015 Oct 23. PMID: 27047023; PMCID: PMC4774661.
Copy Download .nbib Format: NLM
Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis.

Veterinary world

Proverbio D, Spada E, de Giorgi GB, Perego AR.
PMID: 27651682
Vet World. 2016 Aug;9(8):904-8. doi: 10.14202/vetworld.2016.904-908. Epub 2016 Aug 26.

AIM: The aim of this study was to evaluate changes in proteinuria in dogs naturally infected with visceral leishmaniasis, following treatment with miltefosine (MLF) and allopurinol.MATERIALS AND METHODS: Medical records of 40 dogs with leishmaniasis, treated with 2 mg/kg...

Cite
Proverbio D, Spada E, de Giorgi GB, et al. Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis. Vet World. 2016;9(8):904-8doi: 10.14202/vetworld.2016.904-908.
Proverbio, D., Spada, E., de Giorgi, G. B., & Perego, A. R. (2016). Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis. Veterinary world, 9(8), 904-8. https://doi.org/10.14202/vetworld.2016.904-908
Proverbio, Daniela, et al. "Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis." Veterinary world vol. 9,8 (2016): 904-8. doi: https://doi.org/10.14202/vetworld.2016.904-908
Proverbio D, Spada E, de Giorgi GB, Perego AR. Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis. Vet World. 2016 Aug;9(8):904-8. doi: 10.14202/vetworld.2016.904-908. Epub 2016 Aug 26. PMID: 27651682; PMCID: PMC5021843.
Copy Download .nbib Format: NLM
ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches.

Pharmacogenomics and personalized medicine

Cleophas MC, Joosten LA, Stamp LK, Dalbeth N, Woodward OM, Merriman TR.
PMID: 28461764
Pharmgenomics Pers Med. 2017 Apr 20;10:129-142. doi: 10.2147/PGPM.S105854. eCollection 2017.

As a result of the association of a common polymorphism (

Cite
Cleophas MC, Joosten LA, Stamp LK, et al. ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches. Pharmgenomics Pers Med. 2017;10:129-142doi: 10.2147/PGPM.S105854.
Cleophas, M. C., Joosten, L. A., Stamp, L. K., Dalbeth, N., Woodward, O. M., & Merriman, T. R. (2017). ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches. Pharmacogenomics and personalized medicine, 10129-142. https://doi.org/10.2147/PGPM.S105854
Cleophas, M C, et al. "ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches." Pharmacogenomics and personalized medicine vol. 10 (2017): 129-142. doi: https://doi.org/10.2147/PGPM.S105854
Cleophas MC, Joosten LA, Stamp LK, Dalbeth N, Woodward OM, Merriman TR. ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches. Pharmgenomics Pers Med. 2017 Apr 20;10:129-142. doi: 10.2147/PGPM.S105854. eCollection 2017. PMID: 28461764; PMCID: PMC5404803.
Copy Download .nbib Format: NLM
Allopurinol induced stevens - johnson syndrome - a case report.

Journal of clinical and diagnostic research : JCDR

Paik S, Sen S, Das J, Saha B, Tripathi SK.
PMID: 25859508
J Clin Diagn Res. 2015 Feb;9(2):WJ01-2. doi: 10.7860/JCDR/2015/11786.5558. Epub 2015 Feb 01.

No abstract available.

Cite
Paik S, Sen S, Das J, et al. Allopurinol induced stevens - johnson syndrome - a case report. J Clin Diagn Res. 2015;9(2):WJ01-2doi: 10.7860/JCDR/2015/11786.5558.
Paik, S., Sen, S., Das, J., Saha, B., & Tripathi, S. K. (2015). Allopurinol induced stevens - johnson syndrome - a case report. Journal of clinical and diagnostic research : JCDR, 9(2), WJ01-2. https://doi.org/10.7860/JCDR/2015/11786.5558
Paik, Sabyasachi, et al. "Allopurinol induced stevens - johnson syndrome - a case report." Journal of clinical and diagnostic research : JCDR vol. 9,2 (2015): WJ01-2. doi: https://doi.org/10.7860/JCDR/2015/11786.5558
Paik S, Sen S, Das J, Saha B, Tripathi SK. Allopurinol induced stevens - johnson syndrome - a case report. J Clin Diagn Res. 2015 Feb;9(2):WJ01-2. doi: 10.7860/JCDR/2015/11786.5558. Epub 2015 Feb 01. PMID: 25859508; PMCID: PMC4378790.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 641 entries